

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61F 9/007</b>		A1	(11) International Publication Number: <b>WO 00/64390</b>
			(43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/US00/11195 (22) International Filing Date: 26 April 2000 (26.04.00) (30) Priority Data: 60/131,030 26 April 1999 (26.04.99) US (71)(72) Applicants and Inventors: LYNCH, Mary, G. [US/US]; 3845 Club Drive, NE, Atlanta, GA 30319 (US). BROWN, Reay, H. [US/US]; 3845 Club Drive, NE, Atlanta, GA 30319 (US). (74) Agents: WARREN, William, L. et al.; Jones & Askew, LLP, 2400 Monarch Tower, 3424 Peachtree Road, N.E., Atlanta, GA 30326 (US).			(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
			Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: INFLATABLE DEVICE AND METHOD FOR TREATING GLAUCOMA



(57) Abstract

Catheter devices and methods for treating glaucoma and other eye diseases by expandable dilatation of Schlemm's canal and/or direct injection of medications into Schlemm's canal.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

## INFLATABLE DEVICE AND METHOD FOR TREATING GLAUCOMA

10

### Cross - Reference to Related Applications

This application claims the benefit of U.S. Provisional Application No. 60/131,030, filed April 26, 1999.

15

### Technical Field

The present invention is generally directed to a surgical treatment for glaucoma and other eye diseases and relates more particularly to an inflatable device and method for use in ophthalmic surgery to mechanically dilate Schlemm's canal in the eye and/or instill medications within Schlemm's canal for direct action upon the canal, the trabecular meshwork, and adjacent tissues.

### 25 Background of the Invention

Glaucoma is a significant public health problem, because glaucoma is a major cause of blindness. The blindness that results from glaucoma involves both central and peripheral vision and has a major impact on an individual's ability to lead an independent life.

30

Glaucoma is an optic neuropathy (a disorder of the optic nerve) that usually occurs in the setting of an elevated intraocular pressure. The pressure within the eye increases and this is associated with changes in the appearance ("cupping") and function ("blind spots" in the visual field) of the optic nerve. If the pressure remains high enough for a long enough period of time, total vision loss occurs. High pressure develops in an eye because of an internal fluid imbalance.

10           The eye is a hollow structure that contains a clear fluid called "aqueous humor." Aqueous humor is formed in the posterior chamber of the eye by the ciliary body at a rate of about 2.5 microliters per minute. The fluid, which is made at a fairly constant rate, then passes around the lens, through the pupillary opening in the iris and into the anterior chamber of the eye. Once in the anterior chamber, the fluid drains out of the eye through two different routes. In the "uveoscleral" route, the fluid percolates between muscle fibers of the ciliary body. This route accounts for ten percent of the aqueous outflow. The primary pathway for aqueous outflow is through the "canalicular" route that involves the trabecular meshwork and Schlemm's canal.

25           The trabecular meshwork and Schlemm's canal are located at the junction between the iris and the sclera. This junction or corner is called "the angle." The trabecular meshwork is a wedge-shaped structure that runs around the circumference of the eye. It is composed of collagen beams arranged in a three-dimensional sieve-like structure. The beams are lined with a monolayer of cells called trabecular cells. The spaces between the collagen beams are filled with an extracellular substance that is produced by the trabecular cells. These cells also produce enzymes that

degrade the extracellular material. Schlemm's canal is adjacent to the trabecular meshwork. The outer wall of the trabecular meshwork coincides with the inner wall of Schlemm's canal. Schlemm's canal is a tube-like structure that runs around the circumference of the cornea. In human  
5 adults, Schlemm's canal is believed to be divided by septa into a series of autonomous, dead-end canals.

The aqueous fluid travels through the spaces between the trabecular beams, across the inner wall of Schlemm's canal into the canal,  
10 through a series of collecting channels that drain from Schlemm's canal and into the episcleral venous system. In a normal situation, aqueous production is equal to aqueous outflow and intraocular pressure remains fairly constant in the 15 to 21 mm Hg range. In glaucoma, the resistance through the canalicular outflow system is abnormally high.

15 In primary open angle glaucoma, which is the most common form of glaucoma, the abnormal resistance is believed to be along the outer aspect of trabecular meshwork and the inner wall of Schlemm's canal. It is believed that an abnormal metabolism of the trabecular cells leads to an  
20 excessive build up of extracellular materials or a build up of abnormally "stiff" materials in this area. Primary open angle glaucoma accounts for approximately eighty-five percent of all glaucoma. Other forms of glaucoma (such as angle closure glaucoma and secondary glaucomas) also involve decreased outflow through the canalicular pathway but the  
25 increased resistance is from other causes such as mechanical blockage, inflammatory debris, cellular blockage, etc.

With the increased resistance, the aqueous fluid builds up because it cannot exit fast enough. As the fluid builds up, the intraocular

pressure (IOP) within the eye increases. The increased IOP may compromise the vascular supply to the optic nerve that carries vision from the eye to the brain. Some optic nerves seem more susceptible to IOP than other eyes. While research is investigating ways to protect the nerve from an elevated pressure, the only therapeutic approach currently available in  
5 glaucoma is to reduce the intraocular pressure.

The clinical treatment of glaucoma is approached in a step-wise fashion. Medication often is the first treatment option.  
10 Administered either topically or orally, these medications work to either reduce aqueous production or they act to increase outflow. Currently available medications have many serious side effects including: congestive heart failure, respiratory distress, hypertension, depression, renal stones, aplastic anemia, sexual dysfunction and death. Compliance with  
15 medication is a major problem, with estimates that over half of glaucoma patients do not follow their correct dosing schedules.

When medication fails to adequately reduce the pressure, laser trabeculoplasty often is performed. In laser trabeculoplasty, thermal energy  
20 from a laser is applied to a number of noncontiguous spots in the trabecular meshwork. It is believed that the laser energy stimulates the metabolism of the trabecular cells in some way, and changes the extracellular material in the trabecular meshwork. In approximately eighty percent of patients, aqueous outflow is enhanced and IOP decreases. However, the effect often  
25 is not long lasting and fifty percent of patients develop an elevated pressure within five years. The laser surgery is not usually repeatable. In addition, laser trabeculoplasty is not an effective treatment for primary open angle glaucoma in patients less than fifty years of age, nor is it effective for angle closure glaucoma and many secondary glaucomas.

If laser trabeculoplasty does not reduce the pressure enough, then filtering surgery is performed. With filtering surgery, a hole is made in the sclera and angle region. This hole allows the aqueous fluid to leave  
5 the eye through an alternate route.

The most commonly performed filtering procedure is a trabeculectomy. In a trabeculectomy, a posterior incision is made in the conjunctiva, the transparent tissue that covers the sclera. The conjunctiva is  
10 rolled forward, exposing the sclera at the limbus. A partial thickness scleral flap is made and dissected half-thickness into the cornea. The anterior chamber is entered beneath the scleral flap and a section of deep sclera and trabecular meshwork is excised. The scleral flap is loosely sewn back into place. The conjunctival incision is tightly closed. Post-operatively, the  
15 aqueous fluid passes through the hole, beneath the scleral flap and collects in an elevated space beneath the conjunctiva. The fluid then is either absorbed through blood vessels in the conjunctiva or traverses across the conjunctiva into the tear film.

20 Trabeculectomy is associated with many problems. Fibroblasts that are present in the episclera proliferate and migrate and can scar down the scleral flap. Failure from scarring may occur, particularly in children and young adults. Of eyes that have an initially successful trabeculectomy, eighty percent will fail from scarring within three to five  
25 years after surgery. To minimize fibrosis, surgeons now are applying antifibrotic agents such as mitomycin C (MMC) and 5-fluorouracil (5-FU) to the scleral flap at the time of surgery. The use of these agents has increased the success rate of trabeculectomy but also has increased the prevalence of hypotony. Hypotony is a problem that develops when

aqueous flows out of the eye too fast. The eye pressure drops too low (usually less than 6.0 mmHg); the structure of the eye collapses and vision decreases.

5           An alternative surgical method for glaucoma management can be directed more specifically at Schlemm's canal. U.S. Patent No. 5,360,399 teaches the placement of part of a plastic or steel tube into Schlemm's canal with injection of a viscous material through holes in the tube to hydraulically hydrodissect the trabecular meshwork. However, the '399  
10 device provides little or no option for the distance of the hydrodissection within the length of Schlemm's canal, nor suggests a means for dilating the canal to facilitate the natural drainage therefrom.

          A need exists, then, for a system that would allow for precise  
15 dilation and expansion of Schlemm's canal along any portion thereof. A need exists for the selective, direct delivery of therapeutic agents into Schlemm's canal that provides more effective control of glaucoma with fewer systemic complications than with existing medication delivery alternatives. In addition, a more physiologic system is needed to enhance  
20 the drainage of aqueous fluid into Schlemm's canal from the anterior chamber angle. Enhancing aqueous flow directly into Schlemm's canal would minimize scarring since the angle region is populated with a single line of nonproliferating trabecular cells. Enhancing aqueous flow directly into Schlemm's canal and naturally therefrom into the collecting channels  
25 would minimize hypotony since the canal is part of the normal outflow system and is biologically engineered to handle the normal volume of aqueous humor. Enhancing aqueous flow directly into Schlemm's canal would eliminate complications such as endophthalmitis, hypotony, and leaks.



### **Summary of the Invention**

5

The present invention is directed to a novel inflatable catheter device and an associated method for the surgical correction of glaucoma in which the inventive device is placed within Schlemm's canal and the inflatable element of the device is expanded to temporarily stretch and  
10 expand the lumen of the canal. At that point, the inflatable element may be used to temporarily occlude outflow through the canal, while physiologic material is injected through another lumen of the device, thereby distending the canal and expanding areas of stenosis within the canal. The inflated element may be decompressed and removed after the  
15 desired expansion is achieved, or the device may be extracted with the inflatable component expanded, to further mechanically dilate the passageway within Schlemm's canal.

The present invention may also be employed to inject various  
20 medications directly within Schlemm's canal. Such medications may include, but are not limited to, antifibrotics, antibiotics, and other medications which may have direct effects within the internal structures of Schlemm's canal, the trabecular meshwork, and other tissues of the eye. The present invention may also be employed to deploy various stents or  
25 shunts directly within Schlemm's canal to help maintain patency within the canal following removal of the inflatable device.

The inventive device and method described herein therefore facilitates the normal physiologic pathway for drainage of aqueous humor

from the anterior chamber to Schlemm's canal and exiting to the collecting channels, rather than shunting to the sclera or another anatomic site as is done in most prior art devices. In addition, the present invention provides a mechanism for the delivery of devices or medications directly into  
5 Schlemm's canal and the adjacent ophthalmic anatomy.

### **Brief Description of the Drawings**

FIG. 1 is an illustration showing an overall view of one  
10 embodiment of the present invention, in which the inventive device is comprised of a dual, concentric lumen catheter with an outer lumen terminating in an inflatable sleeve, and an inner lumen which protrudes distal to the inflatable sleeve and terminates in an open tip. FIG. 1 further shows a guidewire which extends throughout the length of said catheter.

15

FIG. 2 is an illustration showing a cross sectional view at point A-A' as shown on FIG. 1 and detailing the concentric nature of the two lumens within this embodiment of the present invention.

20

FIG. 3 is an illustration showing a detail of the distal portion of one embodiment of the present invention in which the inventive catheter is configured with the inflatable sleeve operated by the external lumen, and with the internal lumen protruding distally to the inflatable sleeve and containing a plurality of fenestrations before terminating in a blunted tip.

25

FIG. 4 is an illustration showing another possible embodiment of the inventive catheter in which the inflatable sleeve is operated by the internal lumen, and with the external lumen extending to the origin of the inflatable sleeve and containing a plurality of fenestrations.

FIG. 5 is an illustration showing the relevant anatomic details of the human eye.

5           FIG. 6 is an illustration showing the anatomic relationships of the surgical placement of an exemplary embodiment of the present invention within Schlemm's canal.

10           FIG. 7 is a schematic illustration showing the effects on Schlemm's canal (exaggerated for purposes of this illustration) of injection of a medicament by one embodiment of the inventive catheter.

15           FIG. 8 is a schematic illustration showing the effects on Schlemm's canal (exaggerated for purposes of this illustration) of injection of a medicament by one embodiment of the inventive catheter.

### **Detailed Description of Present Invention**

20           The present invention provides catheter devices for the dilatation of Schlemm's canal of the eye by mechanically distending a portion of the canal when inflated. The inflatable catheter devices may also be used to provide a conduit capable of delivering therapeutic and/or expansive medicaments injected therethrough into Schlemm's canal. The inflatable catheter devices may also be used to provide a delivery  
25           mechanism for stents, shunts and the like into Schlemm's canal to maintain patency within the canal to facilitate the natural drainage of aqueous humor. Furthermore, optical fibers, cameras, temperature sensors, pressure sensors, and any other probe or suitable useful device can be delivered to within Schlemm's canal by the present invention.

The invention provides a catheter device comprising a proximal portion manually controllable by a user, and a distal portion shaped and sized for circumferential insertion into a portion of Schlemm's canal. The device further comprises an inflation supply lumen extending from the proximal portion to the distal portion. The distal portion of the inflation supply lumen can be constructed of a resilient, expandable material for radially dilating a portion of Schlemm's canal when inflated. Inflation can be achieved by gas or liquid injection into the proximal portion of the inflation supply lumen, and can be carefully monitored for volume and pressure so as to accurately expand the distal lumen of the catheter device to the desired amount. Therefore, the distal portion of the inflationary lumen can move between a first insertion position and a second inflation position when inflated via the proximal portion.

15

It has not been heretofore determined that Schlemm's canal is patent throughout its circumference in normal individuals, as opposed to being divided by septa into multiple dead end canals. The invention utilizes this new knowledge to access Schlemm's canal and to create and maintain patency within the canal with the present devices.

20

The proximal portion of the catheter device is designed to receive a connector for attachment of an inflation means, such as an injection syringe or pump. The device can also comprise a guiding lumen extending from the proximal portion to the distal portion, wherein the guiding lumen contains a steerable guidewire for directing the catheter device into a desired length of Schlemm's canal.

25

In some embodiments, the catheter device can provide medicinal compositions therethrough for deposit into Schlemm's canal. This can be achieved by utilizing a single lumen with one or more openings or fenestrations in the distal portion thereof. In some cases, the delivery of a medicament may itself be an inert material, such as a gel, to expand and dilate the canal sufficiently, thereby providing a therapeutic effect. Alternatively, the catheter device can have a separate medicament delivery lumen and an inflation lumen, as described above. In certain embodiments, the inflation lumen is concentrically located at a site along the distal portion to provide occlusion of Schlemm's canal either distally or proximally to the material injected.

The present invention is directed to devices and surgical methods for dilating Schlemm's canal and/or for delivering topically active medications directly into Schlemm's canal utilizing an inflatable device that is surgically inserted within at least a portion of Schlemm's canal. The portion of the device extending circumferentially into Schlemm's canal may be fashioned from a flexible, biologically inert material. The distal portion of the catheter device has a diameter approximately equal to that of Schlemm's canal of a human eye. The external diameter of the distal portion can be between about 0.1 and 0.5 mm, or preferably about 0.3 mm. The length of the distal portion can be between about 1.0 and 20 mm, or preferably about 10 mm. The distal portion of the catheter device can have a pre-formed curve having a radius approximately equal to that of Schlemm's canal. The radius of the distal portion can be between about 3 and 10 mm, or preferably about 6 mm.

One embodiment of the present invention is illustrated in FIG. 1, in which the shunt device 100 is shown in a side view. The shunt

device **100** is comprised of two portions, a proximal portion **30** which joins one or more distal portions **40**. The proximal portion **30** is tubular, containing one or more lumens in either a concentric or parallel internal configuration. In the exemplary embodiment of the present invention, the proximal portion **30** is constructed of a biologically inert, flexible material such as silicone or similar polymers. Alternate materials might include, but are not limited to, thin-walled Teflon, polypropylene, or other polymers or plastics.

At its proximal end, the proximal portion **30** is attached to a connector **25** which provides fluid communication between one or more lumens within the proximal portion **30** and standard connectors for medical syringe attachment. In the exemplary embodiment of the present invention, the connector provides such communication with separate subconnectors **10** and **20**. Subconnector **10** terminally connects to syringe attachment **5**, which provides a connection for a syringe [not shown] used to inject materials into one or more communicating lumens within the proximal portion **30**. Subconnector **20** terminally connects to syringe attachment **15**, which provides a connection for a syringe [not shown] used to inject materials into one or more communicating lumens within the proximal portion **30**. Subconnector **20** may also allow passage therethrough for a guidewire **71** with a blunted tip **72**.

The proximal portion **30** of the catheter connects with the distal portion **40**. The lumen(s) of the proximal portion **30** each connect with a corresponding lumen within the distal portion **40**. The distal portion **40** is sized and shaped to be received within Schlemm's canal in the eye. In an alternate embodiment, the distal portion **40** may be a continuous, tapering extension of the proximal portion **30**. The distal portion **40**

terminates in a tip **70** which may be tapered and/or blunted, and may be open or closed. In the embodiment shown in **FIG. 1**, the distal tip of the guidewire **72** extends slightly beyond the tip **70** of the distal portion **40** of the device. In the embodiment shown in **FIG. 1**, the distal portion has a  
5 concentric inflatable sleeve **50**. In an alternate embodiment, distal to the inflatable sleeve **50**, the distal portion **40** may continue as a fenestrated catheter **60**, containing one or more fenestrations **65**.

**FIG. 2** shows a cross section at point A-A' through the  
10 embodiment of the present invention as indicated in **FIG. 1**. In this embodiment, a concentric, dual lumen catheter is provided, with an outer tube **44** and an inner tube **48**. An outer tube lumen **45** is defined between the walls of the outer tube **44** and the inner tube **48**. An inner tube lumen **49** is present within the inner tube **48**.

15  
A longitudinal cross-section detailing the terminal aspect of the distal portion **40** in this embodiment of the present invention is shown in **FIG. 3**. In this embodiment, the outer tube **44** is continuous with the inflatable sleeve **50**, and the outer tube **44** terminates in a sealed end **55** at  
20 the distal end of the inflatable sleeve **50**. The inner tube **48** extends through the center of the inflatable sleeve **50**, and continues distal to the inflatable sleeve **50** as the fenestrated catheter **60**. In the present embodiment, the fenestrated catheter **60** contains a plurality of fenestrations **65**, and terminates in a blunted, sealed distal catheter tip **70**.

25  
In an alternate embodiment of the present invention, as shown in **FIG. 4**, the inflatable sleeve **50** is continuous as a terminal extension of the inner tube **48**, and the device terminates in a blunted distal catheter tip **70** just distal to the inflatable sleeve **50**. In this embodiment of the present

invention, the outer tube **44** is continuous with the fenestrated catheter **60** terminally, such that the fenestrations **65** communicate with the outer lumen **45**. In this embodiment, the inflatable sleeve **50** is controlled through the inner lumen **49**, which is in continuous communication with the lumen of the inflatable sleeve **50**. Any materials intended to be injected into Schlemm's canal are introduced through the outer lumen **45**, and pass through the fenestrations **65** into Schlemm's canal proximal to the inflatable sleeve **50**.

The surgical anatomy relevant to the present invention is illustrated in **FIG. 5**. Generally, **FIG. 5** shows Schlemm's canal **110** and the pupil **120**, with the anatomic relationship of those structures to the anterior chamber **135**, the iris **140**, cornea **145**, trabecular meshwork **150**, and lens **170**.

The surgical placement and functionality of the present invention is shown from a frontal perspective in **FIGS. 6-8**. **FIG. 6** shows the use of an embodiment like that shown in **FIG. 3**, in which the inflatable sleeve **50** is proximal to the fenestrated catheter **60**. The distal portion **40** of the device is threaded into Schlemm's canal **110** through a surgical incision **105**, such that the inflatable sleeve **50** is entirely received into the canal **110**.

The guidewire **71** may be used during surgical placement of the device to afford temporary rigidity to the device to facilitate its placement. Once placement is achieved, the guidewire **71** may be withdrawn, leaving the device **100** in the desired anatomic position.



Once the distal portion **40** of the catheter is satisfactorily placed within Schlemm's canal **110**, the inflatable sleeve **50** is inflated by an injection of liquid material or air through the outer lumen **45** of the catheter. The inflation of the inflatable sleeve **50** serves to seal Schlemm's canal **110**. Subsequent injection of a desired material through the inner lumen **49** of the catheter is expressed through the fenestrated catheter **60**, causing local expansion of Schlemm's canal **110** distal to the inflatable sleeve **50**.

**FIG. 8** shows the functionality of an embodiment like that shown previously in **FIG. 4**, in which the inflatable sleeve **50** is located terminally, and the fenestrations **65** are in the wall of the outer tube **44** towards the catheter tip. When the inflatable sleeve **50** is inflated by injection into the inner tube **48**, Schlemm's canal **110** is effectively sealed distal to the inflated sleeve **50**. Subsequent injection of a desired material through the outer lumen **45** of the catheter is expressed through the fenestrated catheter **60**, causing local expansion of Schlemm's canal **110** proximal to the inflatable sleeve **50**.

The surgical procedure necessary to insert the device requires an approach through a fornix-based conjunctival flap. A partial thickness scleral flap is then created and dissected half-thickness into clear cornea. A radial incision is made at the limbus beneath the scleral flap and deepened until Schlemm's canal is entered posteriorly. The anterior chamber may be deepened with injection of a viscoelastic and a miotic agent. The distal portion of the catheter device is grasped and threaded into Schlemm's canal. At the desired position, the catheter device is inflated to expand Schlemm's canal. The device is then deflated and withdrawn. The scleral flap and conjunctival wound are closed in a conventional manner.

While the above-described embodiments are exemplary, the invention contemplates a wide variety of shapes and configurations of the catheter to provide fluid communication between the anterior chamber and  
5 Schlemm's canal. The above-described embodiments are therefore not intended to be limiting to the scope of the claims and equivalents thereof.

What is claimed is:

1. A catheter device comprising a proximal portion manually controllable by a user, a distal portion sized and shaped for circumferential insertion into a portion of Schlemm's canal, and an inflation supply lumen extending from the proximal portion to the distal portion, wherein the distal portion of the inflationary lumen is expandable and moves between a first Schlemm's canal insertion position and a second Schlemm's canal inflation position when inflated.
2. The catheter device of Claim 1, further comprising a guiding lumen extending from the proximal portion to the distal portion, wherein the guiding lumen contains a steerable guidewire for directing the catheter device into a desired length of Schlemm's canal.
3. The catheter device of Claim 1, further comprising a medicament delivery lumen extending from the proximal portion to the distal portion, wherein the medicament delivery lumen has at least one fenestration therein on the distal portion for the delivery of medicaments into Schlemm's canal.
4. The catheter device of Claim 1, wherein the distal portion has a diameter of about 0.1 to 0.5 mm.
5. The catheter device of Claim 1, wherein the distal portion has a diameter of about 0.3 mm.
6. The catheter device of Claim 1, wherein the distal portion has a length of about 1.0 to 20.0 mm.

7. The catheter device of Claim 1, wherein the distal portion has a pre-formed curvature having a radius which approximates the radius of Schlemm's canal of a human eye.
8. The catheter device of Claim 1, wherein the distal portion has a pre-formed curvature having a radius of between about 3 mm and 10 mm.
9. The catheter device of Claim 1, wherein the distal portion has a pre-formed curvature having a radius of about 6 mm.
10. A catheter device comprising a proximal portion manually controllable by a user, a distal portion sized and shaped for circumferential insertion into a portion of Schlemm's canal, and a medicament delivery lumen extending from the proximal portion to the distal portion, wherein the medicament delivery lumen has at least one fenestration therein on the distal portion for the delivery of medicaments into Schlemm's canal.
11. The catheter device of Claim 10, further comprising a guiding lumen extending from the proximal portion to the distal portion, wherein the guiding lumen contains a steerable guidewire for directing the catheter device into a desired length of Schlemm's canal.
12. The catheter device of Claim 10, further comprising an inflation supply lumen extending from the proximal portion to the distal portion, wherein the distal portion of the inflation supply lumen is

expandable and moves between a first insertion position and a second inflation position when inflated.

13. The catheter device of Claim 10, wherein the distal portion has a diameter of about 0.1 to 0.5 mm.
14. The catheter device of Claim 10, wherein the distal portion has a diameter of about 0.3 mm.
15. The catheter device of Claim 10, wherein the distal portion has a length of about 1.0 to 20.0 mm.
16. The catheter device of Claim 10, wherein the distal portion has a pre-formed curvature having a radius which approximates the radius of Schlemm's canal of a human eye.
17. The catheter device of Claim 10, wherein the distal portion has a pre-formed curvature having a radius of between about 3 mm and 10 mm.
18. The catheter device of Claim 10, wherein the distal portion has a pre-formed curvature having a radius of about 6 mm.
19. A method for the surgical treatment of glaucoma and other diseases, comprising inserting the catheter device of Claim 1 into Schlemm's canal and expanding the canal by inflating the distal portion of the inflation lumen.

20. A method for the surgical treatment of glaucoma and other diseases, comprising inserting the catheter device of Claim 10 into Schlemm's canal and delivering a medicament into the canal through the at least one fenestration in the distal portion of the medicament delivery lumen.

FIG. 1




FIG. 2








FIG 3








Fig. 5




FIG 6




FIG. 7




FIG 8

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/11195

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61F9/007

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 858 788 A (HEIDELBERG ENGINEERING OPTISCH) 19 August 1998 (1998-08-19) column 5, line 6 - line 37 figures 1-4 claims 1,4	10.13-16
Y A		1 3-9.17, 18
Y	US 5 891 084 A (LEE VINCENT W) 6 April 1999 (1999-04-06) column 5, line 40 - line 48 column 7, line 14 - line 54 claim 1	1
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

**Special categories of cited documents:**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 September 2000

Date of mailing of the international search report

05/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mary, C

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/11195

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	US 5 364 374 A (MOORE CHESTER G ET AL) 15 November 1994 (1994-11-15) column 3, line 11 -column 4, line 14 claims 1-11	10,13-18
A	---	1,3-9, 11,12
X	WO 98 23237 A (MORGAN WILLIAM HUXLEY ;YU DAO YI (AU); LIONS EYE INST AUSTRALIA IN) 4 June 1998 (1998-06-04) figures 1-12 page 12, line 9 -page 13, line 6 page 13, line 26 - line 34	10,11
A	---	1-9
P,A	DE 198 40 047 A (NEUHANN THOMAS) 23 March 2000 (2000-03-23) figure 2 column 4, line 46 - line 57	1,2,10, 12
X	US 5 486 165 A (STEGMANN ROBERT) 23 January 1996 (1996-01-23) figures 1-8 column 3, line 5 - line 53 column 4, line 4 - line 14 column 4, line 43 - line 59 claims 1-13	10,13-16
A	---	1,11,12, 17,18
A	US 4 299 227 A (LINCOFF HARVEY A) 10 November 1981 (1981-11-10) column 4, line 26 -column 5, line 50 figures 1A-6B -----	1,10



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/11195

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0858788	A	19-08-1998	DE 19705815 A JP 10248869 A	20-08-1998 22-09-1998
US 5891084	A	06-04-1999	NONE	
US 5364374	A	15-11-1994	AU 4282793 A WO 9320784 A	18-11-1993 28-10-1993
WO 9823237	A	04-06-1998	AU 721915 B AU 5042598 A EP 0967946 A	20-07-2000 22-06-1998 05-01-2000
DE 19840047	A	23-03-2000	WO 0013627 A	16-03-2000
US 5486165	A	23-01-1996	AT 141489 T DE 59206951 D DK 550791 T EP 0550791 A ES 2090420 T JP 6086788 A US 5360399 A	15-09-1996 26-09-1996 09-09-1996 14-07-1993 16-10-1996 29-03-1994 01-11-1994
US 4299227	A	10-11-1981	NONE	

